Immune Thrombocytopenia News and Research

RSS
Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

New study may help identify novel ways to treat immune thrombocytopenia

New study may help identify novel ways to treat immune thrombocytopenia

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Study opens door to new treatment for hard-to-treat asthmatic children

Study opens door to new treatment for hard-to-treat asthmatic children

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Study confirms safety of two measles-containing vaccines

Study confirms safety of two measles-containing vaccines

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions enters into definitive agreement to acquire Cangene

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

One-quarter of ITP patients achieve 5-year treatment-free response

One-quarter of ITP patients achieve 5-year treatment-free response

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

FDA approves changes to REMS for Nplate and Promacta

FDA approves changes to REMS for Nplate and Promacta

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Massive clotting can destroy placenta and cause miscarriages

Massive clotting can destroy placenta and cause miscarriages

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting